FDA Approves First One-Time Treatment for RDEB Wounds

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, compared with 16% in matched control wounds treated with standard of care.Medscape Medical News